Who is eligible for clinical trial NCT07282015?

Participants must meet protocol criteria for Hidradenitis Suppurativa. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07282015 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-19

Real-world Secukinumab Outcomes in Canadian HS Patients (NCT07282015)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (4 items).

Location: Novartis Investigative Site — Calgary, Alberta

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
Adult patients at the time of informed consent signature.
Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
Patients who can understand written and spoken Canadian English or French.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.
Patients who have had any prior exposure to secukinumab (i.e., \>7 days prior to the baseline visit).

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (15 Sites)

Novartis Investigative Site — Calgary, Alberta
Novartis Investigative Site — Calgary, Alberta
Novartis Investigative Site — Winnipeg, Manitoba
Novartis Investigative Site — Fredericton, New Brunswick
Novartis Investigative Site — St. John's, Newfoundland and Labrador
Novartis Investigative Site — Cobourg, Ontario
Novartis Investigative Site — Hamilton, Ontario
Novartis Investigative Site — London, Ontario
Novartis Investigative Site — Markham, Ontario
Novartis Investigative Site — Mississauga, Ontario
Novartis Investigative Site — Richmond Hill, Ontario
Novartis Investigative Site — Toronto, Ontario
Novartis Investigative Site — Saint-Jérôme, Quebec
Novartis Investigative Site — Sherbrooke, Quebec
Novartis Investigative Site — Saskatoon, Saskatchewan

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗